TRIPP PsyAssist Completes Phase 1 Feasibility Study

Demonstrating Promising Results for Virtual Reality as a Pre-Treatment Experience Prior to Ketamine Dosing

Completing the Phase 1 study also sets the stage for future research and development efforts, paving the way for integrating TRIPP PsyAssist’s innovative technology into mainstream clinical practices. To further showcase their groundbreaking research, Reeves will be joined by TRIPP’s Clinical Director of Operations, Sunny Strasburg, and Kadima Neuropsychiatry Institute’s Director, David Feifel, who will be speaking at the upcoming MAPS Psychedelic Science Conference (PS23) in Denver, CO, held from June 19th to June 23rd. Attendees will also have the opportunity to experience TRIPP firsthand at the Kadima booth during the conference, immersing themselves in the transformative potential of the platform.